Skip to Content
Merck
All Photos(1)

Key Documents

R0654

Sigma-Aldrich

Reveromycin A

solid, suitable for cell culture, BioReagent

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C36H52O11
CAS Number:
Molecular Weight:
660.79
MDL number:
UNSPSC Code:
12352207
PubChem Substance ID:
NACRES:
NA.76

product name

Reveromycin A, solid

biological source

Streptomyces sp.

Quality Level

form

solid

mol wt

660.79 g/mol

packaging

pkg of 100 μg

color

tan

solubility

DMF: soluble
DMSO: soluble
ethanol: soluble
ethyl acetate: soluble
methanol: soluble
soluble

antibiotic activity spectrum

fungi

Mode of action

protein synthesis | interferes

shipped in

wet ice

storage temp.

−20°C

SMILES string

[H][C@]1(C\C=C(C)\C=C\[C@H](O)[C@@H](C)\C=C\C(O)=O)O[C@]2(CC[C@@H]1C)CC[C@@](CCCC)(OC(=O)CCC(O)=O)[C@@]([H])(O2)\C=C\C(C)=C\C(O)=O

InChI

1S/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1

InChI key

ZESGNAJSBDILTB-OXVOKJAASA-N

Biochem/physiol Actions

It is an epidermal growth factor (EGF) and eukaryotic cell growth inhibitor.
Reveromycin A is a polyketide antibiotic from Streptomyces sp. Epidermal growth factor (EGF) inhibitor; apoptosis inducer; G1 phase cell cycle inhibitor having antiproliferative behavior against human cell lines KB and K562 as well as antifungal activity.

Analysis Note

Avoid acidic conditions.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Creation of novel reveromycin derivatives by alcohol-added fermentation.
Toshihiko Nogawa et al.
The Journal of antibiotics, 66(4), 247-250 (2012-12-13)
M Tanaka et al.
Journal of dental research, 91(8), 771-776 (2012-06-08)
In osteoprotegerin-deficient (OPG-/-) mice, osteoclast activity causes bone resorption to outpace bone formation, leading to the development of severe osteoporosis. Such mice are therefore useful for investigating the alveolar bone of patients with osteoporosis. Reveromycin A (RM-A) was recently identified
Mariana El Sous et al.
Organic letters, 6(17), 3001-3004 (2004-08-28)
The asymmetric total synthesis of (-)-reveromycin A is described. The key steps involved a Lewis acid catalyzed inverse electron demand hetero-Diels-Alder reaction followed by hydroboration/oxidation to afford the spiroketal core 4 in a highly stereoselective manner and introduction of the
H Koshino et al.
The Journal of antibiotics, 45(9), 1420-1427 (1992-09-01)
Reveromycins A, B, C and D are new group inhibitors of the mitogenic activity of epidermal growth factor (EGF), produced by Streptomyces sp. Reveromycins are novel polyketide type antibiotics which have two terminal carboxylic groups, a spiroketal, a succinate and
Shunji Takahashi et al.
Nature chemical biology, 7(7), 461-468 (2011-06-07)
Spiroacetal compounds are ubiquitous in nature, and their stereospecific structures are responsible for diverse pharmaceutical activities. Elucidation of the biosynthetic mechanisms that are involved in spiroacetal formation will open the door to efficient generation of stereospecific structures that are otherwise

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service